GALT Galectin Therapeutics Inc

Price (delayed)

$2.59

Market cap

$160.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$219.87M

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights
Galectin Therapeutics's quick ratio has increased by 21% YoY and by 13% QoQ
The debt has soared by 65% YoY and by 15% from the previous quarter
GALT's equity has dropped by 64% year-on-year and by 18% since the previous quarter

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
62.15M
Market cap
$160.96M
Enterprise value
$219.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$41.26M
EBITDA
-$41.25M
Free cash flow
-$34.28M
Per share
EPS
-$0.74
Free cash flow per share
-$0.55
Book value per share
-$1.18
Revenue per share
$0
TBVPS
$0.42
Balance sheet
Total assets
$25.89M
Total liabilities
$96.98M
Debt
$82.46M
Equity
-$72.81M
Working capital
$12.83M
Liquidity
Debt to equity
-1.13
Current ratio
2.02
Quick ratio
1.86
Net debt/EBITDA
-1.43
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-185.9%
Return on equity
N/A
Return on invested capital
-70%
Return on capital employed
-311.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
0.39%
1 week
3.19%
1 month
16.14%
1 year
64.97%
YTD
56.02%
QTD
14.6%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$37.38M
Net income
-$44.65M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 11% YoY
The operating income has grown by 3.6% year-on-year

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has decreased by 10% YoY
GALT's equity has dropped by 64% year-on-year and by 18% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
GALT's ROIC is up by 49% YoY and by 15% QoQ
The ROA has grown by 6% from the previous quarter and by 2.1% YoY

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 73% less than its total liabilities
The total liabilities has soared by 54% YoY and by 10% from the previous quarter
Galectin Therapeutics's total assets has increased by 28% YoY but it has decreased by 8% from the previous quarter
The debt has soared by 65% YoY and by 15% from the previous quarter
GALT's equity has dropped by 64% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.